Cigarette smoking and schizophrenia: a specific clinical and therapeutic profile? Results from the FACE-Schizophrenia cohort.
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2017-10-01; 79: 332-339
DOI: 10.1016/j.pnpbp.2017.06.026
Lire sur PubMed
1. Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3;79(Pt B):332-339. doi:
10.1016/j.pnpbp.2017.06.026. Epub 2017 Jun 27.
Cigarette smoking and schizophrenia: a specific clinical and therapeutic
profile? Results from the FACE-Schizophrenia cohort.
Mallet J(1), Le Strat Y(2), Schürhoff F(3), Mazer N(2), Portalier C(2),
Andrianarisoa M(3), Aouizerate B(4), Berna F(5), Brunel L(3), Capdevielle D(6),
Chereau I(7), D’Amato T(8), Denizot H(7), Dubreucq J(9), Faget C(10), Gabayet
F(9), Lançon C(11), Llorca PM(7), Misdrahi D(12), Rey R(8), Roux P(13),
Schandrin A(6), Urbach M(13), Vidailhet P(5), Fond G(14), Dubertret C(2);
FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group.
Collaborators: Andrianarisoa M(15), Aouizerate B(16), Bazin N(17), Berna F(18),
Blanc O(19), Brunel L(15), Bulzacka E(15), Capdevielle D(20), Chereau-Boudet
I(19), Chesnoy-Servanin G(21), Danion JM(18), D’Amato T(21), Deloge A(22),
Delorme C(23), Denizot H(19), Dorey JM(21), Dubertret C(24), Dubreucq J(23),
Faget C(25), Fluttaz C(23), Fond G(26), Fonteneau S(17), Gabayet F(23),
Giraud-Baro E(23), Lacelle D(19), Lançon C(25), Laouamri H(26), Leboyer M(15),
Le Gloahec T(15), Le Strat Y(24), Llorca PM(19), Mallet J(24), Metairie E(25),
Misdrahi D(22), Offerlin-Meyer I(18), Passerieux C(17), Peri P(25), Pires S(19),
Portalier C(24), Ramet L(17), Rey R(21), Roman C(23), Schandrin A(20), Schürhoff
F(15), Tessier A(22), Tronche AM(19), Urbach M(17), Vaillant F(25), Vehier
A(21), Vidailhet P(18), Vilà E(22), Yazbek H(20), Zinetti-Bertschy A(18).
Author information:
(1)Fondation FondaMental, Créteil, France; AP-HP, Department of Psychiatry,
Louis Mourier Hospital, Colombes, France; Inserm U894, France; Université Paris
Diderot, Sorbonne Paris Cité, Faculté de médecine, France. Electronic address:
.
(2)Fondation FondaMental, Créteil, France; AP-HP, Department of Psychiatry,
Louis Mourier Hospital, Colombes, France; Inserm U894, France; Université Paris
Diderot, Sorbonne Paris Cité, Faculté de médecine, France.
(3)Fondation FondaMental, Créteil, France; INSERM U955, Équipe de psychiatrie
translationnelle, Créteil, France; Université Paris-Est Créteil, DHU Pe-PSY,
Pôle de Psychiatrie des Hôpitaux Universitaires H Mondor, Créteil, France.
(4)Fondation FondaMental, Créteil, France; Centre Hospitalier Charles Perrens,
Université de Bordeaux, F-33076 Bordeaux, France; Bordeaux Sleep Clinique,
Pellegrin University Hospital, Bordeaux University, USR CNRS 3413 SANPSY,
Research Unit, 33000 Bordeaux, France; Inserm, Neurocentre Magendie,
Physiopathologie de la Plasticité Neuronale, U862, F-33000 Bordeaux, France.
(5)Fondation FondaMental, Créteil, France; Hôpitaux Universitaires de
Strasbourg, Université de Strasbourg, INSERM U1114, Fédération de Médecine
Translationnelle de Strasbourg, Strasbourg, France.
(6)Fondation FondaMental, Créteil, France; Service Universitaire de Psychiatrie
Adulte, Hôpital la Colombière, CHRU Montpellier, Université Montpellier 1,
Inserm 1061, Montpellier, France.
(7)Fondation FondaMental, Créteil, France; CMP B, CHU, EA 7280 Faculté de
Médecine, Université d’Auvergne, BP 69 63003 Clermont-Ferrand Cedex 1, France.
(8)Fondation FondaMental, Créteil, France; INSERM U1028, CNRS UMR5292, Centre de
Recherche en Neurosciences de Lyon,Université Claude Bernard Lyon 1, Equipe
PSlYR2, Centre Hospitalier Le Vinatier, Pole Est, 95 bd Pinel, BP 30039, 69678
Bron Cedex, France.
(9)Fondation FondaMental, Créteil, France; Centre Référent de Réhabilitation
Psychosociale, CH Alpes Isère, Grenoble, France.
(10)Fondation FondaMental, Créteil, France; Pôle psychiatrie universitaire, CHU
Sainte-Marguerite, F-13274 Marseille Cedex 09, France.
(11)Fondation FondaMental, Créteil, France; Assistance Publique des Hôpitaux de
Marseille (AP-HM), Pôle universitaire de psychiatrie, Marseille, France.
(12)Fondation FondaMental, Créteil, France; Centre Hospitalier Charles Perrens,
Université de Bordeaux, F-33076 Bordeaux, France; CNRS UMR 5287-INCIA, France.
(13)Fondation FondaMental, Créteil, France; Service de psychiatrie d’adulte,
Centre Hospitalier de Versailles, UFR des Sciences de la Santé Simone Veil,
Université Versailles Saint-Quentin en Yvelines, Versailles, France.
(14)Fondation FondaMental, Créteil, France.
(15)INSERM U955, Équipe de psychiatrie translationnelle, Créteil, France;
Fondation Fondamental, France; Université Paris-Est Créteil, DHU Pe-PSY, Pôle de
Psychiatrie des Hôpitaux Universitaires H Mondor, Créteil, France.
(16)Centre Hospitalier Charles Perrens, F-33076 Bordeaux, France; Fondation
Fondamental, France; Université de Bordeaux, Inserm, Neurocentre Magendie,
Physiopathologie de la Plasticité Neuronale, U862, F-33000 Bordeaux, France.
(17)Service de psychiatrie d’adulte, Centre Hospitalier de Versailles, Le
Chesnay, EA 4047 HANDIReSP, UFR des Sciences de la Santé Simone Veil, Université
Versailles Saint-Quentin en Yvelines, Versailles, France; Fondation Fondamental,
France.
(18)Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, INSERM
U1114, Fédération de Médecine Translationnelle de Strasbourg, Strasbourg,
France; Fondation Fondamental, France.
(19)CMP B, CHU, EA 7280 Faculté de Médecine, Université d’Auvergne, BP 69 63003
Clermont-Ferrand Cedex 1, France; Fondation Fondamental, France.
(20)Service Universitaire de Psychiatrie Adulte, Hôpital la Colombière, CHRU
Montpellier, Université Montpellier 1, Inserm 1061, Montpellier, France;
Fondation Fondamental, France.
(21)INSERM U1028, CNRS UMR5292, Centre de Recherche en Neurosciences de Lyon,
Université Claude Bernard Lyon 1, Equipe PSYR2, Centre Hospitalier Le Vinatier,
Pole Est, 95 bd Pinel, BP 30039, 69678 Bron Cedex, France; Fondation
Fondamental, France.
(22)Centre Hospitalier Charles Perrens, F-33076 Bordeaux, France; Université de
Bordeaux, CNRS UMR 5287-INCIA, France; Fondation Fondamental, France.
(23)Centre Référent de Réhabilitation Psychosociale, CH Alpes Isère, Grenoble,
France; Fondation Fondamental, France.
(24)AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, France;
Fondation Fondamental, France; Inserm U894, Université Paris Diderot, Faculté de
médecine, Sorbonne Paris Cité, France.
(25)Assistance Publique des Hôpitaux de Marseille (AP-HM), Pôle universitaire de
psychiatrie, Marseille, France; Fondation Fondamental, France.
(26)Fondation Fondamental, France.
BACKGROUND: Tobacco use is common in patients with schizophrenia (SZ) but little
is known on the role of tobacco in the physiopathology or on the course of the
disease. Only few studies embrace an extensive examination of clinical and
therapeutic characteristics in stabilized patients. The objective of the present
study was to determine the prevalence of tobacco smoking in stabilized SZ
outpatients and the clinical and treatment characteristics associated with daily
tobacco use in a large community-dwelling sample of patients.
METHODS: Three-hundred-and-sixty-one patients were included in the network of
the FondaMental Expert Centers for Schizophrenia. Current tobacco status was
self-declared.
RESULTS: 53.7% were smokers. Mean age at tobacco onset was 17.2years old. In
multivariate analyses, after adjustment for confounding factors, positive
symptoms and mean daily antipsychotic dose were associated with a higher
frequency of tobacco use (OR=1.06 95%IC[1.02-1.12], for positive symptoms,
OR=1.1, 95%IC[1.02-1.18] for daily antipsychotic dose). Education level,
negative symptoms, anticholinergic agents, clozapine or aripiprazole
administration were independently associated with a lower frequency of tobacco
use (respectively OR=0.87, 95%IC [0.79, 0.95], OR=0.95, 95%IC[0.91-0.98],
OR=0.41, 95%IC[0.22-0.76], OR=0.56, 95%IC=[0.32, 0.99] and OR=0.49, 95%IC
[0.26-0.91]).
CONCLUSION: The prevalence of current tobacco smoking in a French
community-dwelling SZ patients is higher that observed in the general
population. Patients with tobacco use present clinical and therapeutic
specificities that may involve interaction between cholinergic-nicotinic and
dopaminergic systems. The present study suggests that some therapeutics may
improve daily smoking behavior in smokers. These results should be confirmed in
longitudinal studies.
Copyright © 2017 Elsevier Inc. All rights reserved.
DOI: 10.1016/j.pnpbp.2017.06.026
PMID: 28663115 [Indexed for MEDLINE]